CHFR Antibody (monoclonal) (M08)
Mouse monoclonal antibody raised against a partial recombinant CHFR.
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, E |
---|---|
Primary Accession | Q96EP1 |
Other Accession | BC012072 |
Reactivity | Human |
Host | mouse |
Clonality | Monoclonal |
Isotype | IgG2a Kappa |
Clone Names | 2B11 |
Calculated MW | 73386 Da |
Gene ID | 55743 |
---|---|
Other Names | E3 ubiquitin-protein ligase CHFR, 632-, Checkpoint with forkhead and RING finger domains protein, RING finger protein 196, CHFR, RNF196 |
Target/Specificity | CHFR (AAH12072.1, 136 a.a. ~ 194 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
Dilution | WB~~1:500~1000 |
Format | Clear, colorless solution in phosphate buffered saline, pH 7.2 . |
Storage | Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
Precautions | CHFR Antibody (monoclonal) (M08) is for research use only and not for use in diagnostic or therapeutic procedures. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
References
CHFR functions as a ubiquitin ligase for HLTF to regulate its stability and functions. Kim JM, et al. Biochem Biophys Res Commun, 2010 May 14. PMID 20388495.Aberrant gene methylation in the peritoneal fluid is a risk factor predicting peritoneal recurrence in gastric cancer. Hiraki M, et al. World J Gastroenterol, 2010 Jan 21. PMID 20082478.Aberrant promoter hypermethylation of the CHFR gene in oral squamous cell carcinomas. Baba S, et al. Oncol Rep, 2009 Nov. PMID 19787237.CHFR promoter hypermethylation and reduced CHFR mRNA expression in ovarian cancer. Gao Y, et al. Int J Biol Markers, 2009 Apr-Jun. PMID 19634111.Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Wu X, et al. Cancer Prev Res (Phila), 2009 Jul. PMID 19584075.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.